Gossamer Bio Inc to Discuss Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis Call Transcript
Good morning. My name is Diana, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer GB Phase II Results Conference Call. (Operator Instructions)
At this time, I would like to turn the conference over to Mr. Bryan Giraudo, Chief Financial Officer. Sir, you may begin.
Thank you, operator, and thank you all for joining us this morning. I am joined on today's call by Gossamer Bio's Co-Founder and Chief Executive Officer, Dr. Sheila Gujrathi; and Vice President of Clinical Development and Medical Lead for the GB001 program, Dr. Hector Ortega.
Earlier this morning, Gossamer Bio issued a press release announcing GB001 top line results from its Phase II LEDA study in patients with moderate to severe eosinophilic asthma and its Phase II TITAN study in patients with chronic rhinosinusitis.
Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |